[1]孔艳艳,周杏琴,曹国宪.N-甲基-D-天冬氨酸受体与脑卒中的关系及其核素显像剂[J].国际放射医学核医学杂志,2010,34(1):6-11.[doi:10.3760/cma.j.issn.1673-4114.2010.01.002]
　KONG Yah-yan,ZHOU Xing-qin,CAO Guo-xian.Relationship between N-methyl-D-aspartate receptor and stroke as well as its nuclide imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):6-11.[doi:10.3760/cma.j.issn.1673-4114.2010.01.002]
点击复制

N-甲基-D-天冬氨酸受体与脑卒中的关系及其核素显像剂(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第1期
页码:
6-11
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Relationship between N-methyl-D-aspartate receptor and stroke as well as its nuclide imaging agents
作者:
孔艳艳1;  周杏琴2;  曹国宪2
1. 200040, 上海, 复旦大学附属华山医院核医学科;
2. 214063, 无锡, 江苏省原子医学研究所, 卫生部核医学重点实验室
Author(s):
KONG Yah-yan1;  ZHOU Xing-qin2;  CAO Guo-xian2
1. Department of Nuclear Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China;
2. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Institute of Nuclear Medicine, Jiangsu Wuxi 214063, China
关键词:
受体; N-甲基-D-天冬氨酸; 脑血管意外; 放射性核素显像
Keywords:
Receptors; N-methyl-D-aspartate; Cerebrovascular accident; Radionuclide imaging
DOI:
10.3760/cma.j.issn.1673-4114.2010.01.002
摘要:
脑卒中具有极高的致死率和致残率,在当今老龄化社会中其危害性日益突出。N-甲基-D-天冬氨酸受体(NMDAR)是一类配体门控离子型谷氨酸受体,参与兴奋性突触传递、突触可塑性和神经精神疾病的发生和发展。NMDAR在不同的脑区分布有差异,如海马和皮层密度最高,这些区域对脑缺血很敏感。谷氨酸介导的兴奋性神经毒对脑卒中的发生、发展起着极其关键的作用,引起了人们对中枢神经系统兴奋性神经递质和NMDAR的高度重视。同时,脑卒中后对Ca2+通透的NMDAR、α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体、海人藻酸受体高度兴奋,引起细胞内钙超载,进而触发级联细胞死亡。NMDAR有特殊的结构和药理学特性,对NMDAR显像剂的研究为脑卒中的早期诊断和研发特异性拮抗剂提供了新的靶点。通过活体断层显像可以观察到缺血缺氧后神经细胞的变化,从而对NMDAR拮抗剂的神经保护作用作出评价。
Abstract:
Stroke is one of the leading causes of death and disability, especially for the old population in modern world. As one of ligand-gating ionotropic glutamate receptors, N-methyl-D-aspartate rece pto r (NMDAR) involves in excitatory synaptic transmission, synaptic plasticity and the cause and development of numerous neurological as well as psychiatric disorders. Since the distribution of NMDAR varies in different regions, certain brain regions such as hippocampus and cortex with the highest density of NMDAR, are especially sensitive to ischemia. Much emphasizes have been put on the changes of excitatory neurotransmission and NMDAR in central nervous system after ischemia, because the glutamate-mediated excitatory neurotoxicity play a key role in the development of stroke. It has been shown that neuronal death after ischemia results from excessive Ca2+ influx, which is due to the hyperactivity of NMDAR, Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor, kainic acid receptors and/or other ion channels permeable to Ca2+. The increase of intracellular Ca2+ triggers the cascades of cell death. With specific structure and pharmacology properties, this study of the tracer of NMDAR give the target for early diagnosis and developing of specific antagonist. Elucidating the changes in interneurons after ischemia/hypoxia with tomography in vivo will help to understand the mechanisms underlying the neoroprotection of antagonist.

参考文献/References:

[1] Xin WK,Zhao XH,Xu J,et al.The removal of extracellular calcium:a novel mechanism underlying the recruitment of N-methyl-D-aspartate (NMDA) receptors in neurotoxicity.Eur J Neurosci,2005,21(3):622-636.
[2] Lau CG,Zukin RS.NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders.Nat Rev Neurosci,2007,8(6):413-426.
[3] 孙凤艳.医学神经生物学.上海:上海科学技术出版社,2008:153-350.
[4] Paoletti P,Neyton J.NMDA receptor subunits:function and pharmacology.Curr Opin Pharmacol,2007,7(1):39-47.
[5] von Engelhardt J,Coserea I,Pawlak V,et al.Excitotoxicity in vitro by NR2A-and NR2B-containing NMDA receptors.Neuropharmacology,2007,53(1):10-17.
[6] Liu Y,Wong TP,Aarts M,et al.NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo.J Neurosci,2007,27(11):2846-2857.
[7] Krebs C,Fernandes HB,Sheldon C,et al.Functional NMDA receptor subtype 2B is expressed in astrocytes after ischemia in vivo and anoxia in vitro.J Neurosci,2003,23(8):3364-3372.
[8] Kemp JA,McKernan RM.NMDA receptor pathways as drug targets.Nat Neurosci,2002,5(Suppl):1039-1042.
[9] Deshpande LS,Lou JK,Mian A,et al.Time course and mechanism of hippocampal neuronal death in an in vitro model of status epilepticus:role of NMDA receptor activation and NMDA dependent calcium entry.Eur J Pharmacol,2008,583(1):73-83.
[10] Lobysheva NV,Tonshin AA,Selin AA,et al.Diversity of neurodegenerative processes in the model of brain cortex tissue ischemia.Neurochem Int,2009,54(5-6):322-329.
[11] Fisher M,Bastan B.Treating acute ischemic stroke.Curr Opin Drug Discov Devel,2008,11(5):626-632.
[12] Hoda MN,Singh I,Singh AK,et al.Reduction of lipoxidative load by secretory phospholipase A2 inhibition protects against neurovascular injury following experimental stroke in rat.J Neuroinflammat,2009,6:21.
[13] Lekishvili T,Hesketh S,Brazier MW,et al.Mouse galectin-1 inhibits the toxicity of glutamate by modifying NR1 NMDA receptor expression.Eur J Neurosci,2006,24(11):3017-3025.
[14] Kiedrowski L.Critical role of sodium in cytosolic[Ca2+] elevations in cultured hippocampal CA1 neurons during anoxic depolarization.J Neurochem,2007,100(4):915-923.
[15] Chazot PL,Lawrence S,Thompson CL.Studies on the subtype selectivity of CP-101,606:evidence for two classes of NR2B-selective NMDA receptor antagonists.Neuropharmaco-logy,2002,42(3):319-324.
[16] Chen M,Lu TJ,Chen XJ,et al.Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance.Stroke,2008,39(11):3042-3048.
[17] Waterhouse RN.Imaging the PCP site of the NMDA ion channel.Nucl Med Biol,2003,30(8):869-878.
[18] Radenovi L,Selakovi V,Andjus PR.Neuroprotection by MK-801 following cerebral ischemia in mongolian gerbils.Arch Biol Sci,2008,60(3):341-346.
[19] Blin J,Denis A,Yamaguchi T,et al.PET studies of [18F]methyl-MK-801,a potential NMDA receptor complex radioligand.Neurosci Lett,1991,121(1-2):183-186.
[20] Wallace MC,Teasdale GM,McCulloch J.Autoradiographic analysis of 3H-MK-801 dizocilpine,in vivo uptake and in vitro binding after focal cerebral ischemia in the rat.J Neurosurg,1992,76(1):127-133.
[21] Owens J,Wyper D J,Patterson J,et al.First SPET images of glutamate (NMDA)receptor activation in vivo in cerebral ischaemia.Nucl Med Commun,1997,18(2):149-158.
[22] Koerner IP,Brambrink AM.Brain protection by anesthetic agents.Curr Opin Anaesthesiol,2006,19(5):481-486.
[23] Owens J,Tebbutt AA,McGregor AL,et al.Synthesis and binding characteristics of N-(1-naphthyl)-N’-(3-125I-iodophenyl)-N’-methylguanidine(125I-CNS 1261):a potential SPECT agent for imaging NMDA receptor activation.Nucl Med Biol,2000,27(6):557-564.
[24] Erlandsson K,Bressan RA,Mulligan RS,et al.Kinetic modelling of[123I] CNS 1261-a potential SPET tracer for the NMDA receptor.Nucl Med Biol,2003,30(4):441-454.
[25] Waterhouse RN,Slifstein M,Dumont F,et al.In vivo evaluation of[11C] N-(2-chloro-5-thiomethylphenyl)-N’-(3-methoxy-phenyl)-N’-methylguanidine([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor.Nucl Med Biol,2004,31(7):939-948.
[26] Görgülü A,Kins T,Cobanoglu S,et al.Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat.Acta Neurochir(Wien),2000,142(11):1287-1292.
[27] Manning SM,Talos DM,Zhou C,et al.NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia.J Neurosci,2008,28(26):6670-6678.
[28] Parsons CG,Danysz W,Quack G.Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonista review of preclinical data.Neuropharmacology,1999,38(6):735-767.
[29] Darlington LG,Mackay GM,Forrest CM,et al.Altered kynurenine metabolism correlates with infarct volume in stroke.Eur J Neurosci,2007,26(8):2211-2221.
[30] Waterhouse RN,Sultana A,Laruelle M.In vivo evaluation of 11C-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6-dichloroindole-2-carboxylic acid (11C-3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel.Nucl Med Biol,2002,29(8):791-794.
[31] Arundine M,Tymianski M.Molecular mechanisms of glutamatedependent neurodegeneration in ischemia and traumatic brain injury.Cell Mol Life Sci,2004,61(6):657-668.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
　Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[3]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[4]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
　Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[5]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
　Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[6]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
　Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[7]周晓靓,王浩,施培基,等.表皮生长因子受体-酪氨酸激酶肿瘤分子显像剂的研究进展[J].国际放射医学核医学杂志,2013,37(2):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
　ZHOU Xiao-liang,WANG Hao,SHI Pei-ji,et al.The developme nt of epidermal growth factor receptor molecular imaging in cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):100.[doi:10.3760/cma.j.issn.1673-4114.2013.02.010]
[8]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
　LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[9]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
　YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[10]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
　BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]

备注/Memo

备注/Memo:
收稿日期:2009-10-28。
基金项目:国家自然科学基金(30770602)
通讯作者:曹闰宪,E-mail:jswxcgx@126.com
更新日期/Last Update: 1900-01-01